Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma

Study Overview
=================
Brief Summary
-----------------
Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).

Official Title
-----------------
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma

Conditions
-----------------
Mesothelioma, Malignant, Gene Abnormality, Pleural Mesothelioma

Intervention / Treatment
-----------------
* Genetic: PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >18 suspected MPM requiring VATS biopsy after multidisciplinary oncologic board validation patient able to understand study objectives and able to give an informed consent patient affiliated to an healthcare society. Exclusion Criteria: pregnancy mental disease, psychiatric disorder patient under protection regimen

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA<br>All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques). | Genetic: PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA<br>* All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| For patients with MPM, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques). | For patients with MPM, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques). | day 1 (day of chirurgie) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
malignant pleural mesothelioma, intra tumoral heterogeneity, genetic abnormalities